This anecdotal evidence comes from a case report of a 15 year old boy with diabetes caused by a gain of function STAT1 mutation who was given Ruxolitinib (a JAK1/JAK2 inhibitor) to treat additional symptoms of this disorder including chronic candidiasis and autoimmune enteropathy (76). This evidence concerns the gene JAK1 and diabetes mellitus.